Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. WALD
WALD logo

WALD Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.190
Open
1.160
VWAP
1.14
Vol
81.66K
Mkt Cap
144.93M
Low
1.095
Amount
92.95K
EV/EBITDA(TTM)
--
Total Shares
128.26M
EV
289.30M
EV/OCF(TTM)
--
P/S(TTM)
0.48
Waldencast plc is a global multi-brand beauty and wellness platform. It is focused on developing, acquiring, accelerating, and scaling conscious and purpose-driven brands. Its segments include Obagi Medical and Milk Makeup. The Obagi Medical segment sells advanced skincare products backed by science and formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines and wrinkles, and to protect and enhance skin tone and texture. Its portfolio of medical-grade skincare with consumer-centric, in-office injectable procedures includes Saypha ChIQ, and MagIQ lines of injectable hyaluronic acid gels. The Milk Makeup segment consists of the business of Milk. Its Milk’s business activities include developing, marketing, and selling cosmetics, skincare, and other beauty products. Its Milk Makeup segment offers over 250 products through its United States Website www.MilkMakeup.com and retail partners include Sephora globally and Ulta Beauty in the United States.
Show More

Events Timeline

(ET)
2026-03-19
08:40:00
Obagi Medical Collaborates with ProMD Health on Hyaluronic Acid Program
select
2026-03-13 (ET)
2026-03-13
07:00:00
Waldencast Reports Q4 Adjusted EBITDA of $6.6M
select
2026-02-27 (ET)
2026-02-27
08:40:00
Obagi Medical Partners with Schweiger Dermatology for Aesthetic Leadership
select
2026-02-25 (ET)
2026-02-25
08:30:00
Obagi Medical Partners with It's a Secret Med Spa
select
2026-02-17 (ET)
2026-02-17
08:40:00
Obagi Medical Partners with Aesthetic Record for Hyaluronic Acid Program
select
2026-02-06 (ET)
2026-02-06
08:30:00
Obagi Medical Partners with DermFx for Hyaluronic Acid Program
select

News

seekingalpha
9.5
03-13seekingalpha
Waldencast Q4 Financial Results Analysis
  • Financial Performance: Waldencast reported a Q4 net loss of $33.5 million, with revenue of $72 million reflecting a slight 0.1% year-over-year decline, yet beating market expectations by $4.2 million, indicating some market resilience.
  • Revenue Sources: Strong growth in Obagi Medical's direct-to-consumer and international channels was offset by softening consumption in Milk Makeup, particularly in international markets, highlighting performance disparities across brands.
  • Market Dynamics: The challenges faced by Waldencast stem primarily from a slowdown in consumer spending in international markets, especially affecting the Milk Makeup brand, which may influence future market strategies and product positioning.
  • Strategic Review: The company is undergoing a strategic review to address current market challenges, ensuring sustainable growth and profitability in the highly competitive beauty industry.
Newsfilter
8.5
02-27Newsfilter
Obagi Partners with Schweiger Dermatology for ALOHA Program Launch
  • Partnership Announcement: Obagi Medical has partnered with Schweiger Dermatology to advance the ALOHA Program, which aims to translate clinical safety and efficacy data from FDA trials into real-world applications, potentially enhancing patient satisfaction and provider-patient relationships.
  • Clinical Research Initiative: The ALOHA Program includes a Phase 4 clinical study led by Dr. David Goldberg, utilizing standardized data capture protocols to evaluate Obagi®saypha®MagIQ™, providing robust clinical evidence for the new injectable's market launch.
  • Marketing Strategy: Through this collaboration, Obagi plans to present initial findings at upcoming industry conferences, highlighting the real-world impact of the new product within the Schweiger network, thereby strengthening its competitive position in the aesthetics market.
  • Technological Innovation: Obagi®saypha®MagIQ™ employs MACRO Core Technology to deliver high usable HA content and consistent gel distribution, ensuring natural-looking results and predictable injection outcomes, further solidifying Obagi's leadership in the professional skincare sector.
Newsfilter
7.5
02-06Newsfilter
Obagi Partners with DermFx for ALOHA Program Launch
  • Strategic Partnership: Obagi Medical has formed a strategic alliance with DermFx to leverage the ALOHA program, translating FDA clinical trial safety and efficacy into practical applications, thereby enhancing DermFx's competitive edge in Southern California.
  • Data-Driven Practice: The program will utilize standardized data capture and structured evaluations across multiple locations to help DermFx deliver superior patient experiences, ultimately increasing patient satisfaction and loyalty.
  • Innovative Technology Application: The Obagi®saypha®MagIQ™ utilizes advanced MACRO Core technology to ensure natural-looking results and high hyaluronic acid content post-injection, enhancing treatment outcomes and market appeal for DermFx.
  • Industry Leadership: This collaboration not only demonstrates Obagi's support for diverse medical practices but also underscores its leadership position in the rapidly growing professional skincare market, expected to drive future business growth.
Newsfilter
7.5
02-05Newsfilter
Obagi Partners with Moxie to Launch ALOHA Program
  • Strategic Partnership: Obagi Medical has partnered with Moxie to launch the ALOHA Program, aimed at leveraging Moxie's all-in-one software and marketing solutions to help med spa entrepreneurs achieve predictable growth and profitability while enhancing clinical and operational excellence.
  • Data-Driven Evaluation: Moxie will conduct a structured assessment of Obagi® saypha® MagIQ™ across its network of supported aesthetic practices, utilizing data-driven insights and expert coaching to generate substantial evidence on the filler’s integration into scalable aesthetic workflows.
  • Enhanced Patient Experience: The ALOHA Program evaluates both clinical performance and patient experience, equipping providers with integrated Obagi protocols to drive satisfaction and loyalty, ensuring consistent treatment outcomes and strengthening market competitiveness.
  • Innovative Technology Application: Obagi® saypha® MagIQ™ utilizes proprietary MACRO Core Technology to deliver natural-looking results and category-leading performance, ensuring high usable HA content upon injection and consistent gel distribution, further solidifying Obagi's leadership in the rapidly evolving aesthetic market.
Newsfilter
5.0
02-03Newsfilter
Obagi Launches New Lip Care Innovations
  • Product Innovation: Obagi has launched two new lip care products, the Lip Therapy AHA + PHA Smoothing Micro-Peel and the SPF 30 Soothe & Protect Lip Treatment, designed to enhance lip health through scientifically-backed formulations that improve user experience.
  • Clinical Validation: The new products have been dermatologist-tested, with users reporting significant improvements in the appearance and feel of their lips, indicating effectiveness in enhancing hydration and reducing fine lines.
  • Market Positioning: Priced at $55 for the Micro-Peel and $40 for the Lip Treatment, these products are expected to be sold through professional channels and will be available on Obagi.com starting February 3, further solidifying Obagi's leadership in the professional skincare market.
  • Brand Strategy: This product launch reflects Obagi's long-standing commitment to skincare innovation, aiming to provide professional-grade care that helps consumers achieve healthy, beautiful skin, thereby enhancing the brand's competitiveness in the rapidly growing skincare market.
Newsfilter
7.5
01-30Newsfilter
Obagi Partners with VIO Med Spa to Launch ALOHA Program
  • Partnership Announcement: Obagi Medical has partnered with VIO Med Spa to launch the ALOHA Program, which aims to conduct a multi-site evaluation of the Obagi® saypha® MagIQ™ filler, leveraging VIO's innovative injectables and personalized wellness protocols to enhance patient outcomes and experiences.
  • Clinical Assessment Focus: The program will standardize data collection to evaluate clinical performance and patient experience, ensuring robust real-world evidence in high-volume aesthetic settings, thereby elevating industry standards and practices.
  • Training Initiative: The ALOHA Program will kick off at the upcoming VIO University training, providing two days of expert-led training for the VIO network, aimed at enhancing clinical excellence and patient satisfaction in aesthetic medicine.
  • Technological Edge: The Obagi® saypha® MagIQ™, developed using Croma-Pharma GmbH's MACRO Core Technology, delivers high usable HA content and consistent gel distribution, ensuring natural-looking results and predictable injection outcomes, further solidifying Obagi's leadership in the professional skincare market.
Wall Street analysts forecast WALD stock price to rise
2 Analyst Rating
Wall Street analysts forecast WALD stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
3.50
Averages
3.75
High
4.00
Current: 0.000
sliders
Low
3.50
Averages
3.75
High
4.00
Alliance Global
Aaron Grey
Buy
downgrade
AI Analysis
2026-03-17
Reason
Alliance Global
Aaron Grey
Price Target
AI Analysis
2026-03-17
downgrade
Buy
Reason
Alliance Global analyst Aaron Grey lowered the firm's price target on Waldencast to $2.50 from $3.50 and keeps a Buy rating on the shares following the Q4 report. The company's EBITDA missed as it has been investing behind the upcoming Saypha injectables launch, the analyst tells investors in a research note. Alliance believes Waldencast remains in its transition period. It thinks the stock's valuation undervalues the brand strength of Obagi and Milk as well as upside from Saypha injectables.
Telsey Advisory
Market Perform
downgrade
$3 -> $2
2026-03-16
Reason
Telsey Advisory
Price Target
$3 -> $2
2026-03-16
downgrade
Market Perform
Reason
Telsey Advisory lowered the firm's price target on Waldencast to $2 from $3 and keeps a Market Perform rating on the shares. The company's Q4 results fell short of expectations, the analyst tells investors. Waldencast is still undergoing a strategic review, which has improved the balance sheet, but recent growth has been slower than expected, the firm adds.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for WALD
Unlock Now

Valuation Metrics

The current forward P/E ratio for Waldencast PLC (WALD.O) is -3.89, compared to its 5-year average forward P/E of 15.79. For a more detailed relative valuation and DCF analysis to assess Waldencast PLC's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
15.79
Current PE
-3.89
Overvalued PE
148.28
Undervalued PE
-116.69

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
14.09
Current EV/EBITDA
14.09
Overvalued EV/EBITDA
18.73
Undervalued EV/EBITDA
9.46

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
2.06
Current PS
0.69
Overvalued PS
3.09
Undervalued PS
1.03

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

predict most bullish ticker next 3 months
Intellectia · 19 candidates
Analyst Consensus: Strong Buy, Moderate BuyMoving Average Relationship: PriceAboveMA20, PriceAboveMA200One Month Rise Prob: >= 65One Month Predict Return: >= 15.0%
Ticker
Name
Market Cap$
top bottom
GPCR logo
GPCR
Structure Therapeutics Inc
4.66B
ANDE logo
ANDE
Andersons Inc
2.19B
NCLH logo
NCLH
Norwegian Cruise Line Holdings Ltd
10.81B
ROG logo
ROG
Rogers Corp
1.98B
TNON logo
TNON
Tenon Medical Inc
8.89M
NI logo
NI
NiSource Inc
21.93B
predict most bullish ticker next 6 months
Intellectia · 3 candidates
Analyst Consensus: Strong Buy, Moderate BuyTarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA20, PriceAboveMA200One Month Rise Prob: >= 75One Month Predict Return: >= 15.0%
Ticker
Name
Market Cap$
top bottom
ROG logo
ROG
Rogers Corp
1.98B
TNON logo
TNON
Tenon Medical Inc
8.89M
WALD logo
WALD
Waldencast PLC
224.36M
bullish signal / value surage stock under 3$
Intellectia · 68 candidates
Price: <= $3.00Relative Vol: >= 1.20Moving Average Relationship: PriceCrossAboveMA5Week Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
ABEV logo
ABEV
Ambev SA
41.38B
OPK logo
OPK
OPKO Health Inc
1.06B
SES logo
SES
SES AI Corp
861.57M
AMC logo
AMC
AMC Entertainment Holdings Inc
825.84M
LXRX logo
LXRX
Lexicon Pharmaceuticals Inc
566.90M
NFE logo
NFE
New Fortress Energy Inc
441.06M

Whales Holding WALD

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Waldencast PLC (WALD) stock price today?

The current price of WALD is 1.13 USD — it has increased 0

What is Waldencast PLC (WALD)'s business?

Waldencast plc is a global multi-brand beauty and wellness platform. It is focused on developing, acquiring, accelerating, and scaling conscious and purpose-driven brands. Its segments include Obagi Medical and Milk Makeup. The Obagi Medical segment sells advanced skincare products backed by science and formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines and wrinkles, and to protect and enhance skin tone and texture. Its portfolio of medical-grade skincare with consumer-centric, in-office injectable procedures includes Saypha ChIQ, and MagIQ lines of injectable hyaluronic acid gels. The Milk Makeup segment consists of the business of Milk. Its Milk’s business activities include developing, marketing, and selling cosmetics, skincare, and other beauty products. Its Milk Makeup segment offers over 250 products through its United States Website www.MilkMakeup.com and retail partners include Sephora globally and Ulta Beauty in the United States.

What is the price predicton of WALD Stock?

Wall Street analysts forecast WALD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WALD is3.75 USD with a low forecast of 3.50 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Waldencast PLC (WALD)'s revenue for the last quarter?

Waldencast PLC revenue for the last quarter amounts to 65.44M USD, decreased

What is Waldencast PLC (WALD)'s earnings per share (EPS) for the last quarter?

Waldencast PLC. EPS for the last quarter amounts to USD, decreased

How many employees does Waldencast PLC (WALD). have?

Waldencast PLC (WALD) has 332 emplpoyees as of March 27 2026.

What is Waldencast PLC (WALD) market cap?

Today WALD has the market capitalization of 144.93M USD.